Profiles of sulfonylurea use in Diabetes Mellitus type 2: an analysis of clinical practice over the last 10 years
Authors' conclusion
These data suggest a consensus, slowly, but increasingly aligning with the current National indications of dismissing SUs for the treatment of T2D. The new drugs for diabetes should represent a preferable choice in all patients who do not have specific contraindications.
Study context
- Population
- T2D patients who started treatment with SUs, Italian Association of Diabetologists (AMD) Annals registry (2010–2020)
- Outcome
- SU prescription and probability of remaining on SU
Methodological detailsregistry-based, Kaplan Meier survival analysis
- Registry-based
- Kaplan Meier survival analysis
Main finding
As reported in the abstract
- SU prescription, 2010
- 30.7 %
- SU prescription, 2020
- 12.9 %
- Probability of staying on SU after one year
- 85.4 %
- Probability of staying on SU after two years
- 75.9 %
- Probability of staying on SU after 3 years
- 68.2 %
- Probability of staying on SU after 5 years
- 56.6 %
Observational data: associations, not effects.
Further findings
Characteristics at SU start · first prescription
- Age, years (mean ± SD)
- 68.2 ± 11.2
- Males
- 55.5 %
- Diabetes duration, years (mean ± SD)
- 10.1 ± 8.3
- BMI, kg/m² (mean ± SD)
- 29.7 ± 5.5
- HbA1c, % (mean ± SD)
- 8.3 ± 1.7 % [67 mmol/mol]
Characteristics of patients who discontinued SUs
- Patients who discontinued SUs had higher BMI and HbA1c, were younger, more often males and treated with insulin
Treatment after switch · over time
- Switch to metformin, DPP-4i, SGLT2i and GLP-1 RA increased; use of glinides, glitazones, acarbose and insulin declined
Original publication
Profiles of sulfonylurea use in Diabetes Mellitus type 2: an analysis of clinical practice over the last 10 years. Diabetes Res Clin Pract. Published 11 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →